Skip to content
About Us

Engineering biology to deliver products so people can access answers to control their health decisions

photo of Sherlock team members in a lab

In 2019, world renowned scientific pioneers and diagnostic veterans came together with a shared belief that bringing the power of CRISPR and synthetic biology to diagnostic development could improve human health. Leveraging an intellectual property portfolio assembled from foundational technologies developed at the Broad Institute and Harvard University’s Wyss Institute, the team founded Sherlock Biosciences to transform these scientific breakthroughs into commercially available products that will make rapid, accurate and affordable diagnostic tests accessible to people at the point of need.

Today, Sherlock continues to disrupt diagnostics, envisioning a world where everyone has access to accurate, actionable health information wherever and whenever it is needed.

65+ patents
20+ publications
60+ employees
$111 million raised to date

Our Investors

Sherlock’s mission is supported by leading investors and global health organizations

Contact us to learn more about how we are engineering biology to test anywhere, everywhere.